Cargando…
Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer
Attempts to directly block the mutant neuroblastoma rat sarcoma oncogene (NRAS) protein, a driving mutation in many cancer types, have been unsuccessful. Current treatments focus on inhibition of different components of NRAS' two main downstream cascades: PI3K/AKT/mTOR and MAPK. Here we test a...
Autores principales: | Vujic, Igor, Sanlorenzo, Martina, Posch, Christian, Esteve-Puig, Rosaura, Yen, Adam J., Kwong, Andrew, Tsumura, Aaron, Murphy, Ryan, Rappersberger, Klemens, Ortiz-Urda, Susana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359268/ https://www.ncbi.nlm.nih.gov/pubmed/25504439 |
Ejemplares similares
-
Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells
por: Vujic, Igor, et al.
Publicado: (2016) -
Mutant NRAS(Q61) shares signaling similarities across various cancer types – potential implications for future therapies
por: Vujic, Igor, et al.
Publicado: (2014) -
The lincRNA MIRAT binds to IQGAP1 and modulates the MAPK pathway in NRAS mutant melanoma
por: Sanlorenzo, Martina, et al.
Publicado: (2018) -
Combined inhibition of MEK and Plk1 has synergistic anti-tumor activity in NRAS mutant melanoma
por: Posch, C, et al.
Publicado: (2015) -
Pharmacological inhibitors of c-KIT block mutant c-KIT mediated migration of melanocytes and melanoma cells in vitro and in vivo
por: Posch, Christian, et al.
Publicado: (2016)